Exhibit 1
CUSIP No. 00448Q201 | 13D | Page 16 of 18 Pages |
AGREEMENT
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Achillion Pharmaceuticals.
This Agreement may be executed in any number of counterparts, each of which shall be deemed an original.
Date: August 25, 2010
Clarus Lifesciences II, L.P. | ||
By: | Clarus Ventures II GP, L.P., its general partner | |
By: | Clarus Ventures II, LLC, its general partner | |
By: | * | |
Robert Liptak | ||
Manager | ||
Clarus Ventures II GP, L.P. | ||
By: | Clarus Ventures II, LLC, its general partner | |
By: | * | |
Robert Liptak | ||
Manager | ||
Clarus Ventures II, LLC | ||
By: | * | |
Robert Liptak | ||
Manager |
* | ||
Nicholas Simon | ||
* | ||
Dennis Henner | ||
* | ||
Jeffrey Leiden | ||
* | ||
Robert Liptak | ||
* | ||
Nicholas Galakatos | ||
* | ||
Kurt Wheeler | ||
* | ||
Michael Steinmetz |
*By: | /s/ Robert Liptak | |
Robert Liptak, for himself and as Attorney-in-Fact |
CUSIP No. 00448Q201 | 13D | Page 17 of 18 Pages |
This Agreement relating to Amendment No. 2 to Schedule 13D was executed by Robert Liptak pursuant to Powers of Attorney, filed with the Securities and Exchange Commission on April 11, 2008, which Powers of Attorney are incorporated herein by reference and copies of which are attached hereto as Exhibit 2.